DeepMed Research

Isosulfan blue

Generic Name: Isosulfan blue

Brand Names: Lymphazurin

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₃N_₂O_₆S_₂

CAS Number: 748080-29-7

Unique Ingredient Identifier: NS6Q291771

Indication: Isosulfan Blue is a synthetic visual lymphatic imaging agent. Isosulfan blue upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities.

Associated Conditions: Chylothorax, Chylous Ascites, Chyluria, Secondary and unspecified malignant neoplasm of lymph nodes, Lymph node response to therapeutic modalities, Lymphedema of the extremities

Clinical Trials

Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Phase 3

Active, not recruiting

Conditions: Breast Cancer Stage II
Breast Cancer Stage I
Breast Cancer Stage III

Interventions: Drug: Isosulfan Blue
Procedure: Axillary Lymph Node Dissection
Other: Quality-of-Life Assessment
Procedure: Mapping
Other: Questionnaire Administration

First Posted Date: 2019-04-25

Last Posted Date: 2025-01-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 534

Registration Number: NCT03927027

Locations: 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States

and more 93 locations

Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery

Not Applicable

Terminated

Conditions: Stage I Endometrial Carcinoma
Stage II Endometrial Carcinoma
Stage III Endometrial Carcinoma
Stage IV Endometrial Carcinoma

Interventions: Procedure: lymph node mapping
Procedure: sentinel lymph node biopsy
Drug: isosulfan blue
Drug: indocyanine green solution
Procedure: therapeutic conventional surgery
Procedure: lymphadenectomy

First Posted Date: 2013-09-11

Last Posted Date: 2020-08-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 58

Registration Number: NCT01939028

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lymph Node Mapping in Patients With Endometrial Cancer

Not Applicable

Completed

Conditions: Endometrial Cancer

Interventions: Procedure: sentinel lymph node detection
Drug: indocyanine green solution
Drug: isosulfan blue
Procedure: sentinel lymph node biopsy

First Posted Date: 2013-03-26

Last Posted Date: 2023-03-22

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 204

Registration Number: NCT01818739

Locations: 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Device: SPY Elite Imaging
Drug: Indocyanine Green
Drug: Isosulfan blue
Drug: 99technetium-sulfur colloid radiolabel

First Posted Date: 2013-01-18

Last Posted Date: 2017-12-11

Lead Sponsor: Stanford University

Target Recruit Count: 23

Registration Number: NCT01771666

Locations: 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States

Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2008-02-28

Last Posted Date: 2013-09-17

Lead Sponsor: Saint John's Cancer Institute

Target Recruit Count: 225

Registration Number: NCT00625625

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Isosulfan blue
Procedure: Axillary Lymph Node Dissection
Procedure: Surgery
Procedure: Sentinel Lymph Node Biopsy
Procedure: Thoracoscopic Surgery
Radiation: Technetium Tc 99m Sulfur Colloid

First Posted Date: 2007-03-22

Last Posted Date: 2017-02-07

Lead Sponsor: University of Miami

Target Recruit Count: 39

Registration Number: NCT00450723

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Isosulfan Blue
Procedure: Lymphangiography
Radiation: Technetium Tc 99m sulfur colloid

First Posted Date: 2007-02-22

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT00438477

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2004-05-19

Last Posted Date: 2013-02-05

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00003186

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

Not Applicable

Terminated

Conditions: Cervical Adenosquamous Carcinoma
Stage I Cervical Cancer
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma

Interventions: Drug: Isosulfan Blue
Procedure: Lymph Node Mapping
Procedure: Lymphangiography
Drug: Methylene Blue
Procedure: Radionuclide Imaging
Procedure: Sentinel Lymph Node Biopsy
Radiation: Technetium Tc-99m Sulfur Colloid
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-10-07

Last Posted Date: 2017-11-06

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 102

Registration Number: NCT00070317

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat

Not Applicable

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2016-03-11

Lead Sponsor: NYU Langone Health

Registration Number: NCT00012168

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy